N-(4-hydroxyphenyl)-retinamide (4HPR) treatment of A2780 ovarian cancer cells can induce PLAB/GDF15 upregulation via a ROS-dependent mechanism [8]. The gene discussed is GDF15; the disease is ovarian cancer.